The threat of triple M and autoimmune overlap syndromes with immune checkpoint inhibitors - A series of case reports

Autoimmun Rev. 2023 Mar;22(3):103269. doi: 10.1016/j.autrev.2023.103269. Epub 2023 Jan 6.

Authors

Ammara Masood¹, Amanda Mootoo², Panayiotis Maghsoudlou³, David D'Cruz², Krishnie Srikandarajah⁴, Mark Harries⁴, Nicholas Hart³, Sophie Papa⁴, James Spicer⁴

Affiliations

¹ Rheumatology Department, Guy's and St. Thomas' Hospitals NHS Foundation Trust, London, UK. Electronic address: masood.ammara@gmail.com.
² Rheumatology Department, Guy's and St. Thomas' Hospitals NHS Foundation Trust, London, UK.
³ Lane Fox Respiratory Medicine Department, Guy's and St. Thomas' Hospitals NHS Foundation Trust, London, UK.
⁴ Department of Medical Oncology, Guy's and St. Thomas' Hospitals NHS Foundation Trust, London, UK.

PMID: 36623629
DOI: 10.1016/j.autrev.2023.103269

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Autoimmune Diseases* / drug therapy
Connective Tissue Diseases*
Humans
Immune Checkpoint Inhibitors
Liver Cirrhosis, Biliary*
Syndrome

Substances

Immune Checkpoint Inhibitors